Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313615 | 0.89 | KMT2A (0.32) | PI4KAPI4K2BPI4K2API4KBNPSR1 | |
| SCHEMBL10275364 | 0.83 | RAB9A (0.33) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL10275894 | 0.79 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL10313618 | 0.74 | XDH (0.37) | PI4KAPI4K2BPI4K2API4KBNPSR1 | |
| SCHEMBL10313617 | 0.73 | RAB9A (0.36) | NPSR1KDRXDH | |
| SCHEMBL10313624 | 0.73 | GRM5 (0.32) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10276158 | 0.72 | KIF11 (0.36) | PI4KAPI4K2BPI4K2API4KBNPSR1 | |
| SCHEMBL10313623 | 0.71 | MEN1 (0.44) | — | |
| SCHEMBL10275265 | 0.65 | CYP17A1 (0.32) | KDR | |
| SCHEMBL10313619 | 0.64 | NFE2L2 (0.36) | PI4KAPI4K2BPI4K2API4KBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PI4KA 2350/4885PI4K2B 3385/4885PI4K2A 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.